Allergic diseases and immunodeficiencies in children, lessons learnt from COVID-19 pandemic by 2022 : A statement from the EAACI-section on pediatrics
© 2022 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd..
By the April 12, 2022, the COVID-19 pandemic had resulted in over half a billion people being infected worldwide. There have been 6.1 million deaths directly due to the infection, but the pandemic has had many more short- and long-term pervasive effects on the physical and mental health of the population. Allergic diseases are among the most prevalent noncommunicable chronic diseases in the pediatric population, and health-care professionals and researchers were seeking answers since the beginning of pandemic. Children are at lower risk of developing severe COVID-19 or dying from infection. Allergic diseases are not associated with a higher COVID-19 severity and mortality, apart from severe/poorly controlled asthma. The pandemic disrupted routine health care, but many mitigation strategies, including but not limited to telemedicine, were successfully implemented to continue delivery of high-standard care. Although children faced a multitude of pandemic-related issues, allergic conditions were effectively treated remotely while reduction in air pollution and lack of contact with outdoor allergens resulted in improvement, particularly respiratory allergies. There is no evidence to recommend substantial changes to usual management modalities of allergic conditions in children, including allergen immunotherapy and use of biologicals. Allergic children are not at greater risk of multisystem inflammatory syndrome development, but some associations with Long COVID were reported, although the data are limited, and further research is needed. This statement of the EAACI Section on Pediatrics provides recommendations based on the lessons learnt from the pandemic, as available evidence.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology - 33(2022), 10 vom: 21. Okt., Seite e13851 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Munblit, Daniel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Allergic diseases |
|---|
| Anmerkungen: |
Date Completed 27.10.2022 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/pai.13851 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347967019 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347967019 | ||
| 003 | DE-627 | ||
| 005 | 20231226035101.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/pai.13851 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1159.xml |
| 035 | |a (DE-627)NLM347967019 | ||
| 035 | |a (NLM)36282136 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Munblit, Daniel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Allergic diseases and immunodeficiencies in children, lessons learnt from COVID-19 pandemic by 2022 |b A statement from the EAACI-section on pediatrics |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.10.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. | ||
| 520 | |a By the April 12, 2022, the COVID-19 pandemic had resulted in over half a billion people being infected worldwide. There have been 6.1 million deaths directly due to the infection, but the pandemic has had many more short- and long-term pervasive effects on the physical and mental health of the population. Allergic diseases are among the most prevalent noncommunicable chronic diseases in the pediatric population, and health-care professionals and researchers were seeking answers since the beginning of pandemic. Children are at lower risk of developing severe COVID-19 or dying from infection. Allergic diseases are not associated with a higher COVID-19 severity and mortality, apart from severe/poorly controlled asthma. The pandemic disrupted routine health care, but many mitigation strategies, including but not limited to telemedicine, were successfully implemented to continue delivery of high-standard care. Although children faced a multitude of pandemic-related issues, allergic conditions were effectively treated remotely while reduction in air pollution and lack of contact with outdoor allergens resulted in improvement, particularly respiratory allergies. There is no evidence to recommend substantial changes to usual management modalities of allergic conditions in children, including allergen immunotherapy and use of biologicals. Allergic children are not at greater risk of multisystem inflammatory syndrome development, but some associations with Long COVID were reported, although the data are limited, and further research is needed. This statement of the EAACI Section on Pediatrics provides recommendations based on the lessons learnt from the pandemic, as available evidence | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a MIS-C | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a allergic diseases | |
| 650 | 4 | |a allergy | |
| 650 | 4 | |a asthma | |
| 650 | 4 | |a care | |
| 650 | 4 | |a children | |
| 650 | 4 | |a eczema | |
| 650 | 4 | |a food allergy | |
| 650 | 4 | |a immunodeficiencies | |
| 650 | 4 | |a lockdown | |
| 650 | 4 | |a long covid | |
| 650 | 4 | |a pandemic | |
| 650 | 4 | |a post-covid-19 condition | |
| 650 | 4 | |a vaccination | |
| 700 | 1 | |a Greenhawt, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Brough, Helen A |e verfasserin |4 aut | |
| 700 | 1 | |a Pushkareva, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Karimova, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Demidova, Anastasia |e verfasserin |4 aut | |
| 700 | 1 | |a Warner, John O |e verfasserin |4 aut | |
| 700 | 1 | |a Kalayci, Omer |e verfasserin |4 aut | |
| 700 | 1 | |a Sediva, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Untersmayr, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez Del Rio, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Vazquez-Ortiz, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Arasi, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Alvaro-Lozano, Montserrat |e verfasserin |4 aut | |
| 700 | 1 | |a Tsabouri, Sophia |e verfasserin |4 aut | |
| 700 | 1 | |a Galli, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Beken, Burcin |e verfasserin |4 aut | |
| 700 | 1 | |a Eigenmann, Philippe A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology |d 1994 |g 33(2022), 10 vom: 21. Okt., Seite e13851 |w (DE-627)NLM075107252 |x 1399-3038 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2022 |g number:10 |g day:21 |g month:10 |g pages:e13851 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/pai.13851 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2022 |e 10 |b 21 |c 10 |h e13851 | ||